HTA Quarterly | Fall 2020
By Xcenda
![North Korean flag with pill](/-/media/assets/xcenda/english/images/hta-quarterly-images/htaq-fall-2020/skoreaflag-on-pill.jpg?h=688&iar=0&w=1375&hash=0EF152305E80D226CE925B7B273B1C51)
HTA QUARTERLY | FALL 2020
Feature Article: 20 Years After the National Health Insurance Act, HTA Policy Changes Reshape Market Access in South Korea
![Image of brain and pills](/-/media/assets/xcenda/english/images/hta-quarterly-images/htaq-fall-2020/alzheimers_treatment.jpg?h=350&iar=0&w=590&hash=51A61CC67564A1E285A04922A8DEC1ED)
HTA QUARTERLY | FALL 2020
Therapeutic Spotlight: New Evidence Brings Cautious Optimism to Alzheimer’s Disease Treatment
![Chinese flag](/-/media/assets/xcenda/english/images/hta-quarterly-images/htaq-fall-2020/chinese_flag.jpg?h=600&iar=0&w=1000&hash=5F33E0336B1E6061C4BB8AA250F32887)
HTA QUARTERLY | FALL 2020
Market Trends and Updates: New Pharmaceutical Policies Have Dramatically Changed the Landscape in China
![People forming a person with a bullhorn](/-/media/assets/xcenda/english/images/hta-quarterly-images/htaq-fall-2020/patient-voice.jpg?h=800&iar=0&w=800&hash=FD64FCA0AAB99B2A83018B091F4E6CC2)
HTA QUARTERLY | FALL 2020
Incorporating the Patient Voice in Value Assessments: The Evolution of ICER’s Approach to Patient Engagement
HTA by the Numbers
$2,340 | $3,120
The price for a typical treatment course of remdesivir for COVID-19 for people covered by government health programs in the United States (US) and other developed countries will be $2,340; the cost will be $3,120 for US patients with private insurance. The announced pricing falls below the cost-effective price range reported by the nonprofit group Institute for Clinical and Economic Review (ICER), which reported a cost-effective price range of $4,580 to $5,080. In 127 poor or middle-income countries, Gilead is allowing generic makers to supply the drug, and two countries have announced doing so for around $600 per treatment course.
Heard on the street
![Syringe and vial](/-/media/assets/xcenda/english/images/hta-quarterly-images/htaq-fall-2020/vaccine.jpg?h=733&iar=0&w=1100&hash=CD695EBFA3DC5F406A936ACB038F063C)